Payment overview · 2025
General Payments
$137.00
6 reported records · 4 companies
Healthcare provider profile · identity verified
Richard Rey Stark, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BOONE, NC · NPI 1023104049
Verified facts
What the public records show
CMS Open Payments records show Richard Rey Stark, M.D. received $137.00 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 317 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.78 | 37.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.49 | 24.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.65 | 21.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.08 | 16.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.00 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.78 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 317 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
317 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
45 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 717 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 619 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 606 | 162 |
| Losartan Potassium | Losartan Potassium | 517 | 143 |
| Lisinopril | Lisinopril | 376 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 119 |
| Omeprazole | Omeprazole | 371 | 108 |
| Gabapentin | Gabapentin | 357 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 351 | 95 |
| Alprazolam | Alprazolam | 349 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 101 |
| Eliquis | Apixaban | 317 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 95 |
| Metformin Hcl | Metformin Hcl | 282 | 75 |
| Cefdinir | Cefdinir | 238 | 162 |
| Tramadol Hcl | Tramadol Hcl | 203 | 54 |
| Azithromycin | Azithromycin | 199 | 141 |
| Lorazepam | Lorazepam | 193 | 32 |
| Simvastatin | Simvastatin | 185 | 44 |
| Trazodone Hcl | Trazodone Hcl | 177 | 57 |
| Allopurinol | Allopurinol | 169 | 49 |
| Montelukast Sodium | Montelukast Sodium | 164 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 61 |
| Potassium Chloride | Potassium Chloride | 151 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 147 | 41 |
| Famotidine | Famotidine | 141 | 47 |
| Sertraline Hcl | Sertraline Hcl | 138 | 35 |
| Methylprednisolone | Methylprednisolone | 136 | 104 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 45 |
| Clonazepam | Clonazepam | 131 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 32 |
| Bupropion Xl | Bupropion Hcl | 117 | 33 |
| Synthroid | Levothyroxine Sodium | 117 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 51 |
| Irbesartan | Irbesartan | 110 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 18 |
| Jardiance | Empagliflozin | 103 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 73 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 30 |
| Mupirocin | Mupirocin | 77 | 44 |
| Glipizide Er | Glipizide | 74 | 22 |
| Finasteride | Finasteride | 72 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 22 |
| Atenolol | Atenolol | 66 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 18 |
| Spironolactone | Spironolactone | 64 | 20 |
| Valsartan | Valsartan | 64 | 18 |
| Diazepam | Diazepam | 62 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 62 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 43 |
| Furosemide | Furosemide | 61 | 27 |
| Meloxicam | Meloxicam | 61 | 17 |
| Valacyclovir | Valacyclovir Hcl | 60 | 28 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Prednisone | Prednisone | 56 | 21 |
| Pregabalin | Pregabalin | 55 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Carvedilol | Carvedilol | 54 | 15 |
| Ramipril | Ramipril | 53 | 13 |
| Warfarin Sodium | Warfarin Sodium | 53 | 12 |
| Celecoxib | Celecoxib | 52 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 37 |
| Ondansetron Odt | Ondansetron | 50 | 17 |
| Ozempic | Semaglutide | 50 | 11 |
| Fluconazole | Fluconazole | 49 | 22 |
| Amoxicillin | Amoxicillin | 48 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 14 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 25 |
| Paxlovid | Nirmatrelvir/Ritonavir | 45 | 44 |
| Estradiol | Estradiol | 44 | 15 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Baclofen | Baclofen | 43 | 13 |
| Glipizide | Glipizide | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 15 |
| Azelastine Hcl | Azelastine Hcl | 40 | 24 |
| Nystatin | Nystatin | 40 | 21 |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Telmisartan | Telmisartan | 37 | 11 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Cephalexin | Cephalexin | 32 | 31 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 13 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 11 |
| Digoxin | Digoxin | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Epinephrine | Epinephrine | 21 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Erythromycin | Erythromycin Base | 17 | 17 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.00 · 6 records | PFIZER INC. | AIRSUPRA, ELIQUIS, NURTEC ODT, REXULTI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error